Table 3 Multivariate analysis for EFS and OS in pediatric patients with AML.

From: Nucleophosmin mutations confer an independent favorable prognostic impact in 869 pediatric patients with acute myeloid leukemia

Outcome

Variable

Hazard ratio (95% CI)

P-value

EFS

NPM1

0.473 (0.283–0.790)

0.004

FLT3/ITD

1.743 (1.296–2.345)

<0.001

SCT

0.575 (0.419–0.790)

0.001

Age >10

1.098 (0.889–1.356)

0.387

Abnormal cytogenetics

1.058 (0.789–1.420)

0.705

OS

NPM1

0.452 (0.242–0.841)

0.012

FLT3/ITD

1.600 (1.132–2.263)

0.008

SCT

0.824 (0.580–1.171)

0.280

Age >10

1.192 (0.924–1.538)

0.176

Abnormal cytogenetics

0.995 (0.707–1.401)

0.977

  1. CI confidence interval, EFS event-free survival, FLT3/ITD internal tandem duplication of the FLT3 gene, OS overall survival, SCT stem cell transplantation
Back to article page